HYPOMYOPATHIC DERMATOMYOSITIS COMPLICATED BY MANNOSE-BINDING LECTIN DEFICIENCY
Mariam Al-Attar 1 , and Rachel Gorodkin 2 1 Rheumatology, Manchester Royal Infirmary, Manchester, United Kingdom, and 2 Kellgren Centre, Manchester Royal Infirmary, Manchester, United Kingdom Introduction: Connective tissue diseases can present a diagnostic odyssey both for the patient and the practitioner. Here, the clinicaljourney of a patient with hypomyopathic dermatomyositis and mannose-binding lectin deficiency is described, demonstrating the interaction between complex co-morbidities and highlighting the importance of recognising different phenotypes of dermatomyositis. The case addresses the therapeutic challenges of conflicting immunological requirements, the importance of monitoring for infective complications, and is also a rare example of long-term IVimmunoglobulin therapy. Case description: A 47-year-old female with no significant medical history presented with an insect bite on her breast which subsequently began to discharge and ulcerate, unresponsive to oral antibiotics. Shortly after, shedeveloped painful swelling of fingers, knees, ankles and shoulders, followed by widespread itching and a blistering rash on her arms, upper torso and face. Examination was remarkable for peri-orbital oedema, retinal cotton wool spots and alopecia. Her investigations at this time revealed positive ANA, anti-Ro and raised CK. Skin biopsy was suggestive of dermatomyositis, but MRI of thighs, EMG and nerve conduction studies were normal. Other results included raised ESR, low lymphocytes and normal CRP. An initial diagnosis of SLE/dermatomyositis overlap was made; she was treated with IV methylprednisolone and discharged on hydroxychloroquine and prednisolone. Following this, she developed new areas of extensive and dramatic vasculitic skin ulceration on her face, fingers and elbows. Immunosuppressive therapy was escalated with increased dose of hydroxychloroquine and commencement of azathioprine. However, she then developed recurrent infections at the site of the ulcers as well as two episodes of infective tenosynovitis. Despite reduction of immunosuppression, she required multiple admissions to hospitals for intravenous antibiotics. Eventually, investigation into her recurrent infections revealed a complete, homozygous mannose-binding lectin (MBL) deficiency. In light of her severe symptoms and obvious risk for ongoing immunosuppression, it was decided that she would be a candidate for IV immunoglobulin (IVIG) therapy. Monitoring the evolution of the clinical picture over time led to a diagnosis of hypomyopathic dermatomyositis, positive for MDA-5 autoantibody. She has responded well to the IVIG with improvement of skin manifestations and no further infections. She has developed pulmonary fibrosis, but this has been extremely well controlled. However, her disease has been further complicated by the development of a peripheralneuropathy, which is still currently under investigation. Discussion: This is a fascinating case of a rare subset of dermatomyositis, thetreatment ofwhichwascomplicatedbyconcurrentMBLdeficiency.Itis interestingtonotethatMBLdeficiencyisactuallyimplicatedinthedevelopment of autoimmune conditions, in particular dermatomyositis. Other immunodeficiency conditions linked to dermatomyositis include X-linked agammaglobulinaemiaandhemophagocyticlymphohistiocytosis. As specialists who regularly use immunosuppressive agents, it is important for rheumatologists to be vigilant about the potential for infective complications, and to consider investigating for another underlying diagnosis if infections become more recurrent or severe than expected. Indeed, in the case of MBL deficiency, there would likely never be any clinical manifestation without precipitation by additional immunosuppressive therapy. This diagnosis prompted the decision to use regular IVIG therapywhich hasbeen successfulin controlling the disease. It is interesting to note that the patient is anti-MDA-5 antibody positive, which characteristically produces an amyopathic phenotype with rapidly progressive interstitial lung disease. In fact, her lung disease has been extremely stable and mostly asymptomatic. Whether this is due to the IVIG isunclear.A2018casereportdescribedanMDA-5positivedermatomyositis/scleroderma overlap without ILD and with sensory neuropathy. This also raises the question of whether her neurological manifestations could be linked to dermatomyositis. Initially, she presented with bilateral sensory neuropathy in both feet, and it was thought to be a potential feature of her condition. However, she subsequently developed sudden loss of power in her leg, and further investigations have concluded that she most likely has multiplesclerosis(MS).ThisiscertainlyplausibleduetoherunderlyingMBL deficiency which predisposes her to development of autoimmune conditions, but it would be interesting to discuss whether this could potentially stillbeapartofthedermatomyositis.
i18 26 September 2019 POSTER PRESENTATIONS Key learning points: The firstlearningpoint from this case is to take asystematic approach to the diagnosis of connective tissue diseases. With so many overlapping symptoms and signs, and indeed, so many overlapping diagnoses, it is imperative that one takes a thorough and comprehensive multi-system history and examination. We have also gained an awareness of hypo-or amyopathic myositis as rare phenotypes of dermatomyositis, which will allow us to improve diagnostic acumen if faced with patients with the characteristic rashes and little or no muscle weakness. This case has also prompted us to actively consider whether new symptoms in patients with dermatomyositis can be explained by the diagnosis or whether they necessitate a search for further explanation. This is an important consideration when dealing with any patients with a multi-system disease. Without an open mind and appropriate investigation, underlying or secondary diagnoses can easily be missed. The recurrent infections could have been attributed to the immunosuppressive therapy alone, or else considered to be an expected complication of severe and widespread of skin breakdown, but fortunately was recognised and investigated appropriately.
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The authors have declared no conflicts of interest. Introduction: Statins are frequently prescribed, following or in order to prevent cardiovascular events. They inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoA), an enzyme involved in cholesterol synthesis. Up to 20% of patients experience myalgia which resolve after the drug is stopped. We highlight a more serious and potentially lifethreatening complication: statin-induced autoimmune necrotising myositis (SIANM). Recently SIANM has been differentiated from inflammatory polymyositis. Patients present with bilateral proximal muscle weakness, elevated creatinine kinase, a muscle biopsy with necrosis and a positive HMGCoA reductase antibody. The latter has been found to be a specific and sensitiveinvestigation forSIANM. Case description: Given the rarity of SIANM, no guidelines available recommend a best course of treatment, here we highlight 3 successfully treatedpatients. Case 1: 72-year-old man with hypercholesterolaemia, type 2 diabetes and hypertension presented with progressive proximal symmetrical weakness for 6 months. He started 20mg atorvastatin a year earlier and stopped this 2 months before admission. Examination revealed 4/5 muscle strength proximally in all 4 limbs and the patient struggled to stand from sitting. CK was elevated at 8223 IU/L (30-200). EMG confirmed a myopathic process and MRI thighs showed active inflammation. A muscle biopsy and HMGCoA antibodies confirmed SIANM and the patient commenced IV and then oral steroids. The patient deteriorated rapidly over the subsequent days with progressive weakness and dysphonia. He developed bilateral pneumonias and was admitted to ITU.
Here we commenced the patient on IV immunoglobulin (IVIG) and rituximab. With this he improved significantly,withincreasing power and a nor-malisedCK. Case 2: 55-year-old old man with a background of previous MI in 2013 (after which he commenced atorvastatin), type 2 diabetes, hypercholesterolemia and hypertension presented with progressive bilateral proximal muscle weakness. Serum CK found to be 8413, his statin was stopped and the patient underwent extensive investigation. Once again investigations confirmed the diagnosis of SIANM. The patient commenced steroid treatment but despite initial improvement in his power, this soon plateaued as did his CK. He was commenced on IVIG and methotrexate and found significant benefit withthese treatments. Case 3: 60-year-old lady presented with a 5-month history of generalised aches and pains with difficulty standing from sitting. She had been on atorvastatin for many years but her symptoms did not improve despite having stopped this 5 months previously. Investigations confirmed a SIANM. The patient was commenced on steroids and methotrexate with good effect. Discussion: Patients presenting on statins with proximal symmetrical weakness and a raised CK should have HMGCOA antibodies checked as part of a myositis screen. Though statins should always be stopped, patients with SIANM can continue to deteriorate despite drug discontinuation and steroid treatment. Such patients should be considered for immunosuppression. The 3 cases described show positive response to a combination of methotrexate, IVIG and/or rituximab. This seems to mirror the growing clinical experience in other published case reports. Key learning points: Patients presenting on statins with proximal symmetrical weakness and a raised CK should have HMGCOA antibodies checkedas partof amyositis screen. Withdrawal of the statin and steroid treatment alone is often insufficient to successfully treat SIANM. Close monitoring of a patient's power and CK levels are required even after withdrawal of a statin and treatment with steroid as patients can continue todeteriorate. In such cases, additional treatment with methotrexate, IVIG and/ or rituximab appearsto have the best outcomes. Conflicts of interest: The authors have declared no conflicts of interest. Nerve conduction studies revealed normal sensation, and most motor nerves had normal conduction velocities with small nerve responses. Electromyography showed areas withdenervation. With no improvement in the patient's condition, anti-tuberculosis and anti-fungal therapy were commenced, with pulsed methylprednisolone for three days followed by 80mg daily to cover for an organizing pneumonia. Subsequent cultures were negative. Progressive weight loss with muscle wasting ensued and later, facial hyperpigmentation was noted in addition to the development of facial, lip and arms swelling. He was rheumatoid factor positive >500 iu/ml, with a raised IgE 2912 g/L and IgG 37.6 g/L. A CT-PET scan revealed intense uptake in the muscles posterior of the neck, tongue and masticators. An MRI scan of his arms revealed several abnormal signals around the shoulder girdle, long muscles of the back, and upper arm, which guided the site for muscle biopsy. This revealed highly abnormal skeletal muscle with frequent atrophic and necrotic fibres overrun by macrophages and T-cell rich inflammation. These findings in addition to serology reporting the presenceof anti-SAE antibodies confirmed the diagnosis. Pulsed methylprednisolone, immunoglobulin therapy, and azathioprine were initiated with reducing prednisolone dose. Discussion: This case of DM with a generalised rash, severe dysphagia and limb subcutaneous oedema were salient features in addition to the presence of anti-SAE antibodies. Anti-SAE has been shown to be present exclusively in DM patients where rash and severe dysphagia are common clinical findings. Our patient presented with severe dysphagia, which can be difficult to manage requiring enteral feeding. Video fluoroscopy was particularly useful in this case helping to stratify the severity of dysphagia and we would urge other clinicians to use this tool when investigating patients with suspected dermatomyositis to avoid potential complications of poor swallow including aspiration pneumonia. The additional imaging modality of PET-CT in our case confirmed the involvement of the
